Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thromboembolism 1Sarcoma 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 3aflibercept 2Taxes 2Specimen Handling 2Psychiatric Rehabilitation 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Fentanyl 2Cisplatin 2Carboplatin 2tinostamustine 1sodium thiosulfate 1rucaparib 1pelcitoclax 1motexafin lutetium 1entinostat 1cobimetinib 1X-Rays 1Topotecan 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Serotonin Plasma Membrane Transport Proteins 1Ropivacaine 1Radiotherapy 1Radiation 1Quality of Life 1Polymerase Chain Reaction 1Platinum 1Patient Reported Outcome Measures 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Fondaparinux × Sarcoma × Clear all
NCT00381888 2017-12-28

Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
44 enrolled 7 charts
GynecologicSarcoma

Carcinoma, Ovarian Epithelial, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Thromboembolism, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡